Daiichi Sankyo Licenses ERS Genomics’ CRISPR Gene Editing Tech
Pharmaceutical Technology's In the Lab eNewsletter
The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.
Japan-based pharmaceutical company Daiichi Sankyo has signed a license agreement with Ireland-based biotechnology company ERS Genomics for ERS Genomics’ CRISPR/Cas9 genome-editing technology intellectual property for use in internal R&D. The agreement was announced on Jan. 13, 2020, and financial terms were not disclosed.
ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications except for use as a human therapeutic. Under the agreement, Daiichi Sankyo is able to use CRISPR technology to support its R&D initiatives to address areas of unmet medical need.
“Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations,” said Eric Rhodes, CEO of ERS Genomics, in a company press release.
Source: ERS Genomics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
